What is igritumomab?

ibritumomab is a medicine that is primarily used to treat non-hodgkin's lymphoma, a form of cancer that affects white blood cells known as lymphocytes. These cells are found in the lymphatic system, a number of tissues and organs that help the body to fight the disease. Non-Hodgkin's lymphoma causes the growth of abnormal cells in lymphocytes to form tumors, which can prevent the lymphatic system from functioning properly. The effectiveness of the drug in the treatment of non-Hodgkin's lymphoma may depend on how advanced cancer is and how far it has spread throughout the body.

It is generally assumed that ibritumomab may be effective in the treatment of non-hodgkin lymphoma by connection to cancer cells in lymphocytes. The drug mimics the protein found in the immune system that can connect to specific cell types. Once the drug is connected to a cancer white bloodstream, then it destroys them using a radioactable. Many doctors usually recommend taking medication in conjunction with rituximab, another drug that connectsAnd it destroys certain cancer cells.

Ibritumomab is available as a solution administered intravenously. Since drugs can potentially damage healthy cells and organs, it is usually administered only by a doctor as a bed or outpatient procedure to monitor the patient during administration. The amount of dose and the number of treatment can vary very much depending on the severity of the disease and how the person's body reacts to drugs.

Although Ibritumomab should destroy abnormal cancer cells, it can potentially affect healthy cells and cause certain side effects. Side effects often disappear after regular treatment with treatment and usually do not require medical care. More effects often affect bleeding and include blood into urine or stool, nose bleeding, coughing, heavier menstrual bleeding than usual and excessive or longer permanent blood from cuts or scratches. Other common side effects that canOU also occur, such as fatigue, headache, dizziness, pain in the lower back and shortness of breath.

Ibritumomab can also contribute to long -term side effects that may not be seen up to weeks or years after treatment. Medicines can change red blood cell levels and potentially cause a person to obtain anemia, a condition in which a person has reduced the number of red blood cells. Since red blood cells are responsible for supplying oxygen throughout the body, reduced cells may prevent sufficient oxygen transport and cause symptoms such as dizziness, breathing and fatigue problems. If anemia occurs, it generally develops at least six weeks after the initial treatment. In rare cases, medicines can also create a persy more likely to develop a second form of cancer years after initial treatment.